us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $91.73

    as of June 12, 2025
  • YTD RETURNS
    6.93%

    as of June 12, 2025
  • Total Net Assets
    $581.38M

    as of June 12, 2025
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

About PPH

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Overview

Why PPH

  • Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
  • Industry Leaders: Index methodology favors the largest companies in the industry
  • Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Sector Weightings (%) as at 05/31/2025

  • Sector

    % of Net Assets
  • Health Care

    99.63
  • Other/Cash

    0.37

Country Weightings (%) as at 05/31/2025

  • Country

    % of Net Assets
  • United States

    59.93
  • United Kingdom

    15.20
  • Switzerland

    5.56
  • Denmark

    4.98
  • Israel

    4.78
  • Japan

    4.72
  • France

    4.46
  • Other/Cash

    0.37

Distributions

Team

Literature

PPH